Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of previously treated advanced chronic lymphocytic leukemia (CLL)~  * Fludarabine-refractory disease~ * Requires treatment~PATIENT CHARACTERISTICS:~* Life expectancy more than 6 months~* ECOG 0-2~* No severe organ dysfunction~* No other concomitant or previous neoplasms~* No autoimmune hemolytic anemia or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Up to 5 prior chemotherapy regimens allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).